Thread by @ZdenekVrozina

We are still trying to place Long COVID into a biologically coherent framework.
This study is interesting because immune activation, antiviral signaling, metabolism, mitochondria, cell survival do not appear as separate findings - but as parts of one connected system🧵

https://twitter.com/evelio_prieto/status/2055776954284941453

A possible axis is this
something keeps innate immunity on alert - immune cells produce inflammatory signals - their metabolism shifts - mitochondria come under stress - stressed mitochondria can further amplify immune activation.
That is a loop, not a list.

The study compared 50 people with Long COVID with 50 recovered controls around 10 months after SARS-CoV-2.
Both groups had been infected. The key difference was whether symptoms persisted.

The Long COVID group reported symptoms across several systems, most often neuropsychiatric, musculoskeletal, and respiratory symptoms.
So the biological signal is being seen in a clinically multisystem condition - not in an isolated abnormality.

The study also linked several markers to overall symptom burden.
HIF-1α, IL-1β, IL-10, and NRF1 remained strongly associated with symptom burden.
That makes the immune-metabolic-mitochondrial axis especially interesting.

These markers map onto plausible symptom biology.
Inflammation may contribute to pain, fatigue, and brain fog.
HIF-1α points toward hypoxia/metabolic stress.
NRF1/DRP1/PARKIN suggest mitochondrial remodeling, which may connect to energy limitation and PEM.

First layer. Antiviral signaling.
Higher OAS1 and MAVS suggest that innate immunity may still be behaving as if it is responding to a viral or antiviral trigger months later.
The study does not tell us whether this means a reservoir, leftover antigen, or signaling that failed to switch off.

Second. Inflammation.
Higher IL-1β and IL-6 point to inflammatory activation. But IL-10 and SOCS3 were also higher - signals that usually reflect regulation or braking.
So this does not look like simple inflammation. It looks more like an immune system that is activated and restrained at the same time.

And this is where metabolism matters.
An activated immune cell does not use energy like a resting cell. It changes its metabolic program, alters mitochondrial function, and often shifts into a mode useful for defense but not necessarily for long-term balance.

A key hub here is HIF-1α.
It connects inflammation, hypoxia, glycolysis, mitochondrial stress, and immune-cell activation.
In this study, it was one of the markers most strongly associated with symptom burden.

So inflammation here may not be just an immune signal.
It may also be a sign that immune cells have shifted into a different metabolic state - and that state can help keep inflammation going.

Third layer. Mito.
Higher NRF1, DRP1, and PARKIN together suggest mitochondrial remodeling. The cell may be trying to rebuild mitochondria, split them, and remove damaged parts.
That looks more like a stress adaptation than a random finding.

This is where the loop closes.
Inflammation stresses mitochondria. Stressed mitochondria can send danger signals, alter the cell’s redox state, and feed back into immune pathways.
So mitochondria are not only victims of inflammation. They may also amplify it.

Fourth layer. Cell survival.
Higher MCL1 and LIVIN suggest that some activated or stressed cells may survive longer than expected.
That could prolong the time during which the immune system remains in this altered state.

Epigenetics may fit into this picture too.
The study did not measure it directly. But when immune cells remain metabolically shifted, their metabolites can influence chromatin, histones, and DNA methylation.
That is one way cells can acquire a kind of memory of an inflammatory state.

So the connection matters.
Antiviral signaling may drive inflammation. Inflammation shifts metabolism. Metabolism reshapes mitochondria. Mitochondria feed signals back to immunity. And epigenetics may help stabilize the whole pattern.

This study offers a model in which several regulatory systems may keep each other locked in an unfavorable loop.

The loop is not directly proven by this study. It is an interpretive model built from the pattern of gene-expression shifts.
What the study shows is that antiviral, inflammatory, metabolic, mitochondrial, and cell-survival genes move together in a way that is biologically coherent - and several of them track with symptom burden.

That is clinically important.
If Long COVID is a network of dysregulation, one universal biomarker may not be enough.
We need to better understand which layer dominates in which patient - antiviral, inflammatory, mitochondrial, autonomic, vascular, or metabolic.

Ali at al., Integrated immune, apoptotic and mitochondrial gene dysregulation in Long COVID and their association with symptom burden at 10 months post-infection. nature.com/articles/s4159…